

# ADX-PSA Metastatic Prostate Cancer

## Phase 1/2 Combination ± KEYTRUDA® (pembrolizumab)



ADVAXIS  
IMMUNOTHERAPIES™

### Inclusion Criteria:

- Pretreated metastatic CRPC
- <3 prior systemic treatment regimens or >1 prior regimen in the metastatic setting

### Part B Expansion: Endpoints

- Safety
- Efficacy
- Immunologic Activity

WEEK 1      WEEK 4      WEEK 7      REPEAT Q 12 WEEK CYCLES

### Part A ADX-PSA Monotherapy

- n=21
- Dose escalation (3 dose levels)

### Endpoints:

- Safety
- RP2D

Up to PD or  
2 years

ADX-PSA      ADXS-PSA      ADXS-PSA

### Part B ADX-PSA + pembrolizumab

- n=30 (up to 21 in part B, remainder in expansion)
- Dose determination & confirmation

### Endpoints:

- Safety
- RP2D of the combination

Up to PD or  
2 years

Pembrolizumab      Pembrolizumab      Pembrolizumab